Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance
Zubair A. Qureshi,Lauren E. Hittle,Jessica A. O'Hara,Jesabel I. Rivera,Alveena Syed,Ryan K. Shields,Anthony W. Pasculle,Robert K. Ernst,Yohei Doi +8 more
TLDR
Colistin-resistant A. baumannii occurred almost exclusively among patients who had received CMS for treatment of carbapenem-resistant, colist in-susceptible, and -resistant isolates, suggesting evolution of resistance during CMS therapy.Abstract:
Background. With an increase in the use of colistin methansulfonate (CMS) to treat carbapenem-resistant Acinetobacter baumannii infections, colistin resistance is emerging. Methods. Patientswithinfection orcolonizationdue tocolistin-resistantA.baumanniiwere identifiedat ahospital system in Pennsylvania. Clinical data were collected from electronic medical records. Susceptibility testing, pulsed-field gel electrophoresis (PFGE), and multilocus sequence typing (MLST) were performed. To investigate the mechanism of colistin resistance, lipid A was subjected to matrix-assisted laser desorption/ionization mass spectrometry. Results. Twenty patients with colistin-resistant A. baumannii were identified. Ventilator-associated pneumonia was the most common type of infection. Nineteen patients had received intravenous and/or inhaled CMS for treatment of carbapenem-resistant, colistin-susceptible A. baumannii infection prior to identification of colistin-resistant isolates. The 30-day all-cause mortality rate was 30%. The treatment regimen for colistin-resistant A. baumannii infection associated with the lowest mortality rate was a combination of CMS, a carbapenem, and ampicillin-sulbactam. The colistin-susceptible and -resistant isolates from the same patients were highly related by PFGE, but isolates from different patients were not, suggesting evolution of resistance during CMS therapy. By MLST, all isolates belonged to the international clone II, the lineage that is epidemic worldwide. Phosphoethanolamine modification of lipid Awas present in all colistin-resistant A. baumannii isolates. Conclusions. Colistin-resistant A. baumannii occurred almost exclusively among patients who had received CMS for treatment of carbapenem-resistant, colistin-susceptible A. baumannii infection. Lipid A modification by the addition of phosphoethanolamine accounted for colistin resistance. Susceptibility testing for colistin should be considered for A. baumannii identified from CMS-experienced patients.read more
Citations
More filters
Journal ArticleDOI
Antimicrobial resistance in ESKAPE pathogens
David M. P. De Oliveira,Brian M. Forde,Timothy J. Kidd,Patrick N A Harris,Mark A. Schembri,Scott A. Beatson,David L. Paterson,Mark J. Walker +7 more
TL;DR: The acquisition of antimicrobial resistance genes by ESKAPE pathogens has reduced the treatment options for serious infections, increased the burden of disease, and increased death rates due to treatment failure and requires a coordinated global response for antim antibiotic resistance surveillance.
Journal ArticleDOI
Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.
Darren Wong,Travis B. Nielsen,Robert A. Bonomo,Paul Pantapalangkoor,Brian Luna,Brad Spellberg,Brad Spellberg +6 more
TL;DR: Given its high rate of antibiotic resistance and abysmal outcomes (up to 70% mortality rate from infections caused by XDR strains in some case series), new preventative and therapeutic options for Acinetobacter spp.
Journal ArticleDOI
Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance
TL;DR: The theory behind antivirulence strategies is outlined, the recent successes and failures of this paradigm, and new developments that are in the pipeline are discussed.
Journal ArticleDOI
International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).
Brian T. Tsuji,Jason M. Pogue,Alexandre P. Zavascki,Mical Paul,Mical Paul,George L. Daikos,Alan Forrest,Daniele Roberto Giacobbe,Claudio Viscoli,Helen Giamarellou,Ilias Karaiskos,Donald Kaye,Johan W. Mouton,Vincent H. Tam,Visanu Thamlikitkul,Richard G. Wunderink,Jian Li,Roger L. Nation,Keith S Kaye +18 more
TL;DR: In this paper, the authors report consensus therapeutic guidelines for agent selection and dosing of colistin and polymyxin antibiotics for optimal use in adult patients, as endorsed by the American College of Clinical Pharmacy (ACCP), Infectious Diseases Society of America (IDSA), International Society of Anti-Infective Pharmacology (ISAP), Society for Critical Care Medicine (SCCM), and Society of Infectious diseases Pharmacists (SIDP).
Journal ArticleDOI
Mechanisms of antimicrobial resistance in Gram-negative bacilli
TL;DR: The burden of multidrug resistance in Gram-negative bacilli (GNB) now represents a daily issue for the management of antimicrobial therapy in intensive care unit (ICU) patients, and recent reports emphasizing the spread of colistin resistance in environments with high volume of polymyxins use elicit major concern.
References
More filters
Performance standards for antimicrobial susceptibility testing
TL;DR: The supplemental information presented in this document is intended for use with the antimicrobial susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute (CLSI)–approved standards.
Journal ArticleDOI
Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.
Fred C. Tenover,Robert D. Arbeit,Richard V. Goering,P. A. Mickelsen,Barbara E Murray,D. H. Persing,B. Swaminathan +6 more
TL;DR: This research presents a novel, scalable and scalable approach that allows for real-time assessment of the severity of the infection and its impact on patients’ health.
Journal ArticleDOI
CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting.
TL;DR: In this paper, the NHSN criteria for all healthcare-associated infections (HAIs) are presented, including those for the "Big Four" (surgical site infection [SSI], pneumonia [PNEU], bloodstream infection [BSI] and urinary tract infection [UTI]).
Journal Article
CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting.
TL;DR: In this article, the NHSN criteria for all healthcare-associated infections (HAIs) are presented, including those for the "Big Four" (surgical site infection [SSI], pneumonia [PNEU], bloodstream infection [BSI] and urinary tract infection [UTI]).
Related Papers (5)
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
A-P Magiorakos,Arjun Srinivasan,R B Carey,Yehuda Carmeli,Matthew E. Falagas,Matthew E. Falagas,Christian G. Giske,Stéphan Juergen Harbarth,Janet F. Hindler,Gunnar Kahlmeter,Barbro Olsson-Liljequist,David L. Paterson,Louis B. Rice,John Stelling,Marc Struelens,Alkiviadis Vatopoulos,J T Weber,Dominique L Monnet +17 more